Trials / Completed
CompletedNCT00579670
Treatment of Schizophrenic Patients With Ziprasidone
Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.
Detailed description
Sampling Method Details: Non-interventional study (subjects chosen by physician in accordance to their usual practice).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ziprasidone | Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2007-12-24
- Last updated
- 2021-03-10
- Results posted
- 2010-05-17
Locations
20 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT00579670. Inclusion in this directory is not an endorsement.